© 2021 MJH Life Sciences™ and Contemporary OB/GYN. All rights reserved.
All News
2021: A year in review
December 03, 2021
Contemporary OB/GYN® has aimed to address prevalent topics for our readers, including not only areas related to the pandemic but ones we encounter day to day.
Making waves in breast cancer prevention
December 03, 2021
“This vaccine strategy has the potential to be applied to other tumor types,” said Vincent K. Tuohy, PhD, the Mort and Iris November Distinguished Chair in Innovative Breast Cancer Research at Cleveland Clinic Lerner Research Institute, and primary inventor of the vaccine.
S3E20: Brooke Faught, NP on sexual health, trauma-informed care, and the perks of meeting in-person
December 03, 2021
In this episode of Pap Talk, we took you with us to the North American Menopause Society's recent Annual Meeting. Sexual health specialist Michael Krychman, MD, sat down with Brooke Faught, NP, to learn more about her work at the Women's Institute for Sexual Health, her role on the NAMS Planning Committee, and her tips for talking trauma with patients.
Laser for postmenopausal vaginal symptoms
December 02, 2021
For women with postmenopausal vaginal symptoms, fractional carbon dioxide laser versus sham treatment fails to significantly improve vaginal symptoms after 12 months, according to the results of a randomized controlled trial in JAMA.
Pregnancy Experts Call for Medicaid Policy Change
December 01, 2021
Patients Desiring Immediate Postpartum Sterilization Should Not Be Required to Wait 30 Days.
FDA grants olaparib priority review in BRCA-mutated HER2-negative high-risk early breast cancer
December 01, 2021
Olaparib, which was granted priority review by the FDA, has been shown to improve invasive disease-free survival for patients with BRCA-mutated HER2-negative high-risk early breast cancer.
Retifanlimab shows promising antitumor activity in advanced endometrial cancer
December 01, 2021
Retifanlimab demonstrated encouraging antitumor activity with favorable tolerability in patients with recurrent microsatellite instability–high or mismatch repair deficient endometrial cancer, according to data from the phase 1 POD1UM-101 trial.
FDA investigating impact of Omicron on available mitigation strategies
December 01, 2021
The US Food and Drug Administration (FDA) is currently investigating whether the new COVID-19 variant will evade current mitigation strategies and diagnostic tools.
What you need to know right now about the COVID-19 Omicron variant
November 30, 2021
An update from infectious disease expert, Rana F. Hamdy, MD, on the Omicron variant of COVID-19.